Trial reportBMJ (Clinical research ed.)2006
Impact of Helicobacter pylori eradication on dyspepsia, health resource use, and quality of life in the Bristol helicobacter project: randomised controlled trial.
Trial report in BMJ (Clinical research ed.), 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 5 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- First regional consensus on the management ofWorld journal of gastroenterology · 2025Guideline
- Helicobacter pylori eradication for the prevention of gastric neoplasia.The Cochrane database of systematic reviews · 2020Pooled it
- Helicobacter pylori eradication for the prevention of gastric neoplasia.The Cochrane database of systematic reviews · 2015Pooled it
- Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials.BMJ (Clinical research ed.) · 2014Pooled it
- [Clinical practice guideline on the management of patients with dyspepsia. Update 2012].Atencion primaria · 2012Guideline
- Efficacy of Helicobacter pylori eradication regimens in Rwanda: a randomized controlled trial.BMC gastroenterology · 2018Trial
- Barriers to Community-Based Eradication of Helicobacter pylori Infection.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2024Article
- Current and Future Perspectives on the Management ofAntibiotics (Basel, Switzerland) · 2024Review
- Who Needs Gastroprotection in 2020?Current treatment options in gastroenterology · 2020Review
- Review of current diagnostic methods and advances inWorld journal of gastroenterology · 2019Review
- Article
- Prevalence ofJournal of clinical and diagnostic research : JCDR · 2017Article
- Population screening and treatment of Helicobacter pylori infection.Nature reviews. Gastroenterology & hepatology · 2017Review
- New Diagnostic Strategies for Detection of Helicobacter pylori Infection in Pediatric Patients.Gastroenterology & hepatology · 2014Article
- Managing dyspepsia.Current gastroenterology reports · 2009Review
- Estimating drug costs in economic evaluations in Ireland and the UK: an analysis of practice and research recommendations.PharmacoEconomics · 2009Review
- Eradication of helicobacter pylori to prevent gastroduodenal diseases: hitting more than one bird with the same stone.Therapeutic advances in gastroenterology · 2008Article
- Non-invasive diagnosis of H pylori infection: evaluation of serological tests with and without current infection marker CIM.World journal of gastroenterology · 2008Article
- Contemplating the future without Helicobacter pylori and the dire consequences hypothesis.Helicobacter · 2007Review
- Dyspepsia and Helicobacter pylori.BMJ (Clinical research ed.) · 2007Review
Corrections and comments
- Commented on by
Authors and funding
8 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine the impact of a community based Helicobacter pylori screening and eradication programme on the incidence of dyspepsia, resource use, and quality of life, including a cost consequences analysis.
designH pylori screening programme followed by randomised placebo controlled trial of eradication.
settingSeven general practices in southwest England.
participants10,537 unselected people aged 20-59 years were screened for H pylori infection (13C urea breath test); 1558 of the 1636 participants who tested positive were randomised to H pylori eradication treatment or placebo, and 1539 (99%) were followed up for two years.
interventionRanitidine bismuth citrate 400 mg and clarithromycin 500 mg twice daily for two weeks or placebo.
main outcome measuresPrimary care consultation rates for dyspepsia (defined as epigastric pain) two years after randomisation, with secondary outcomes of dyspepsia symptoms, resource use, NHS costs, and quality of life.
resultsIn the eradication group, 35% fewer participants consulted for dyspepsia over two years compared with the placebo group (55/787 v 78/771; odds ratio 0.65, 95% confidence interval 0.46 to 0.94; P = 0.021; number needed to treat 30) and 29% fewer participants had regular symptoms (odds ratio 0.71, 0.56 to 0.90; P = 0.05). NHS costs were 84.70 pounds sterling (74.90 pounds sterling to 93.91 pounds sterling) greater per participant in the eradication group over two years, of which 83.40 pounds sterling (146 dollars; 121 euro) was the cost of eradication treatment. No difference in quality of life existed between the two groups.
conclusionsCommunity screening and eradication of H pylori is feasible in the general population and led to significant reductions in the number of people who consulted for dyspepsia and had symptoms two years after treatment. These benefits have to be balanced against the costs of eradication treatment, so a targeted eradication strategy in dyspeptic patients may be preferable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.